Education
About Us
Working with TipRanks
Follow Us
Kymera Therapeutics (KYMR)
NASDAQ:KYMR
Total Valuation
Kymera Therapeutics has a market cap or net worth of $1.43B. The enterprise value is $2.82B.
Market Cap$1.43B
Enterprise Value$2.82B
Share Statistics
Kymera Therapeutics has 64.94M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding64.94M
Owened by Insiders28.27%
Owened by Instutions0.06%
Financial Efficiency
Kymera Therapeutics’s return on equity (ROE) is -0.27 and return on invested capital (ROIC) is -28.33%.
Return on Equity (ROE)-26.79%
Return on Assets (ROA)-22.89%
Return on Invested Capital (ROIC)-28.33%
Return on Capital Employed (ROCE)-28.74%
Revenue Per Employee$250,382.979
Profits Per Employee-$1,190,734.043
Employee Count188
Asset Turnover0.05
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Kymera Therapeutics is -13.49. Kymera Therapeutics’s PEG ratio is -0.74.
PE Ratio-13.49
PS Ratio64.14
PB Ratio3.61
Price to Fair Value3.61
Price to FCF-14.56
Price to Operating Cash Flow-15.52
PEG Ratio-0.74
Income Statement
In the last 12 months, Kymera Therapeutics had revenue of $47.07M and earned -$223.86M in profits. Earnings per share was -$2.97.
Revenue$47.07M
Gross Profit$41.67M
Operating Income-$256.71M
Pretax Income-$223.86M
Net Income-$223.86M
EBITDA-216.22M
Earnings Per Share (EPS)-2.97
Cash Flow
In the last 12 months, operating cash flow was -$194.50M and capital expenditures -$12.84M, giving a free cash flow of -$207.34M billion.
Operating Cash Flow-$194.50M
Free Cash Flow-$207.34M
Free Cash Flow per Share-$3.19
Dividends & Yields
Kymera Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-6.87%
Earnings Yield-7.41%
Stock Price Statistics
Beta2.53
52-Week Price Change-39.32%
50-Day Moving Average34.17
200-Day Moving Average41.24
Relative Strength Index (RSI)24.49
Average Volume (3m)752.77K
Important Dates
Kymera Therapeutics upcoming earnings date is May 1, 2025, Before Open.
Last Earnings DateFeb 27, 2025
Next Earnings DateMay 1, 2025
Ex-Dividend Date―
Financial Position
Kymera Therapeutics as a current ratio of 7.53, with Debt / Equity ratio of 0.11
Current Ratio7.53
Quick Ratio7.53
Debt to Market Cap0.03
Net Debt to EBITDA0.15
Interest Coverage Ratio-1.05K
Taxes
In the past 12 months, Kymera Therapeutics has paid $39.00K in taxes.
Income Tax$39.00K
Effective Tax Rate0.00%
Enterprise Valuation
Kymera Therapeutics EV to EBITDA ratio is -13.81, with an EV/FCF ratio of -14.40.
EV to Sales63.45
EV to EBITDA-13.81
EV to Free Cash Flow-14.40
EV to Operating Cash Flow-15.35
Balance Sheet
Kymera Therapeutics has $488.74M in cash and marketable securities with $87.76M in debt, giving a net cash position of -$400.98M billion.
Cash & Marketable Securities$488.74M
Total Debt$87.76M
Net Cash-$400.98M
Net Cash Per Share-$6.17
Tangible Book Value Per Share$11.14
Margins
Gross margin is 100.00%, with operating margin of -555.82%, and net profit margin of -475.57%.
Gross Margin100.00%
Operating Margin-555.82%
Pretax Margin-475.57%
Net Profit Margin-475.57%
EBITDA Margin-459.37%
EBIT Margin-475.04%
Analyst Forecast
The average price target for Kymera Therapeutics is $55.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$55.00
Price Target Upside149.21%
Analyst ConsensusStrong Buy
Analyst Count12
Revenue Growth Forecast-40.11%
EPS Growth Forecast-17.79%